Our previous study enrolled patients with HCC, CCA, or combined hepatocellular-cholangiocarcinoma, in which a protein biomarker pool containing 57 entities to discriminate the patients from the controls was established and the clinical relevance of different glycosylation patterns on complement C3 in HCC was subsequently analyzed [6]. The gene discussed is C3; the disease is cholangiocarcinoma.